| Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis MG Levra, FE Cotté, R Corre, C Calvet, AF Gaudin, JR Penrod, ... Lung Cancer 140, 99-106, 2020 | 101 | 2020 |
| Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting JB Assié, C Chouaïd, H Nunes, D Reynaud, AF Gaudin, V Grumberg, ... Therapeutic Advances in Medical Oncology 15, 17588359231152847, 2023 | 5 | 2023 |
| MA07. 06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting MG Levra, F Cotté, R Corre, C Calvet, B Jouaneton, R Jolivel, A Gaudin, ... Journal of Thoracic Oncology 14 (10), S274-S275, 2019 | 3 | 2019 |
| P2. 04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting J Assié, F Cotte, MG Levra, C Calvet, R Jolivel, B Jouaneton, A Gaudin, ... Journal of Thoracic Oncology 14 (10), S708, 2019 | 3 | 2019 |
| Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD V Aboyans, O Morboeuf, B Grenier, R Jolivel, A Bura-Riviere European Journal of Vascular and Endovascular Surgery, 2024 | 2 | 2024 |
| Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France V Grumberg, C Chouaïd, FE Cotté, B Jouaneton, R Jolivel, AF Gaudin, ... Journal of Medical Economics 25 (1), 691-699, 2022 | 2 | 2022 |
| Couts des hospitalisations et des soins de suite et de réadaptation liés au COVID-19 en France en 2020 S Gallien, C Guilmet, A Hurtes, H Omichessan, F Messaoudi, A Panes, ... Médecine et Maladies Infectieuses Formation 1 (2), S51, 2022 | 2 | 2022 |
| Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study) C Chouaid, MG Levra, R Corre, C Calvet, AF Gaudin, V Grumberg, ... Annals of Oncology 30, v521, 2019 | 2 | 2019 |
| Patients en vie 5 ans après l’initiation de nivolumab dans le cancer bronchique non à petites cellules métastatique: caractéristiques, prise en charge et consommations de soins JB Assié, FE Cotté, D Reynaud, AF Gaudin, V Grumberg, R Jolivel, ... Revue des Maladies Respiratoires Actualités 15 (1), 237, 2023 | 1 | 2023 |
| 101P Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting JB Assie, C Chouaïd, H Nunes, D Reynaud, AF Gaudin, V Grumberg, ... Annals of Oncology 32, S1418, 2021 | 1 | 2021 |
| Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national … JB Assié, V Grumberg, D Reynaud, AF Gaudin, A Batisse, R Jolivel, ... Respiratory Medicine and Research 84, 101051, 2023 | | 2023 |
| EPH15 Epidemiology of Patients Revascularized for Peripheral Artery Disease in France (2016-19): A Retrospective Observational Cohort Study Using the French Hospital Discharge … V Aboyans, H Miadi, O Morboeuf, E Piettre, R Jolivel, A Bura-Rivière Value in Health 25 (12), S193, 2022 | | 2022 |
| POSA300 Combining Clinical Trial and Real-World Evidence Data in the Assessment of Public Health Impact in HTA Evaluations H Leleu, A Nucit, C Lefevre, O Salvignol, B Grenier, C Coulibaly, R Jolivel, ... Value in Health 25 (1), S198, 2022 | | 2022 |
| POSC418 Long-Term Evolution of Hospital Resource Utilization and Associated Costs Using Adjustment Methods: in Patients Treated with Nivolumab for Advanced Non-Small Cell Lung … V Grumberg, C Chouaid, FE Cotte, B Jouaneton, R Jolivel, AF Gaudin, ... Value in Health 25 (1), S271, 2022 | | 2022 |
| PCN138 Study of the Burden of Blood Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes Who Receive Regular Transfusions G Jeanblanc, Q Roset, A Schmidt, B Jouaneton, R Jolivel Value in Health 23, S448, 2020 | | 2020 |
| PCN348 Long-Term Healthcare Resource Utilization and Costs Associated with Patients Treated with Nivolumab for Advanced Non-Small Cell Lung Cancer V Grumberg, FE Cotte, B Jouaneton, R Jolivel, R Corre, M Giaj-Levra, ... Value in Health 23, S484, 2020 | | 2020 |
| PDB74 USING FRENCH ADMINISTRATIVE DATABASE TO ASSESS PATIENTS WITH ADVANCED NON-ALCOHOLIC STEATOHEPATITIS (NASH) V Ratziu, F Raguideau, R Jolivel, A Vainchtock, I Rodriguez, A Abergel Value in Health 22, S586, 2019 | | 2019 |
| Prise en charge hospitalière des exacerbations de BPCO et impact sur les réadmissions en France L De Léotoing, B Melloni, A Cavailles, T Flament, G Berthon, F Raguideau, ... Revue des Maladies Respiratoires 36, A66, 2019 | | 2019 |
| PRS30-HOSPITAL MANAGEMENT OF ACUTE COPD EXACERBATION AND IMPACT ON HOSPITAL RE-ADMISSION IN FRANCE L de Léotoing, B Melloni, A Cavaillès, T Flament, F Raguideau, R Jolivel, ... Value in Health 21, S408-S409, 2018 | | 2018 |
| PND109-SICKLE-CELL DISEASE RELATED HOSPITALIZATIONS IN FRANCE: A REGIONAL DESCRIPTIVE ANALYSIS FROM THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE IN 2016 E Duteil, F Raguideau, R Jolivel, A Pagniez, L Lamarsalle Value in Health 21, S347, 2018 | | 2018 |
